A new trading day began on Monday, with Syndax Pharmaceuticals Inc (NASDAQ: SNDX) stock price down -3.06%% from the previous day of trading, before settling in for the closing price of $9.48. SNDX’s price has ranged from $8.58 to $25.07 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -15.16% over the past five years. Meanwhile, its annual earnings per share averaged -1.15%. With a float of $82.47 million, this company’s outstanding shares have now reached $86.05 million.
Let’s look at the performance matrix of the company that is accounted for 270 employees. In terms of profitability, gross margin is -3.44%, operating margin of -786.59%, and the pretax margin is -757.52%.
Syndax Pharmaceuticals Inc (SNDX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Syndax Pharmaceuticals Inc is 4.16%, while institutional ownership is 116.11%. The most recent insider transaction that took place on May 16 ’25, was worth 105,826. In this transaction Head of R&D, CMO of this company bought 11,765 shares at a rate of $8.99, taking the stock ownership to the 35,165 shares. Before that another transaction happened on May 19 ’25, when Company’s Director bought 5,000 for $8.99, making the entire transaction worth $44,950. This insider now owns 79,000 shares in total.
Syndax Pharmaceuticals Inc (SNDX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -1.15% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.52% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Here are Syndax Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.09.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.87, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -2.67 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) saw its 5-day average volume 1.95 million, a negative change from its year-to-date volume of 2.2 million. As of the previous 9 days, the stock’s Stochastic %D was 6.67%.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 7.29%, which indicates a significant increase from 2.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.00% in the past 14 days, which was lower than the 76.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.10, while its 200-day Moving Average is $14.66. Nevertheless, the first resistance level for the watch stands at $9.47 in the near term. At $9.75, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.93. If the price goes on to break the first support level at $9.01, it is likely to go to the next support level at $8.83. Assuming the price breaks the second support level, the third support level stands at $8.55.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
With a market capitalization of 790.78 million, the company has a total of 86,047K Shares Outstanding. Currently, annual sales are 23,680 K while annual income is -318,760 K. The company’s previous quarter sales were 20,040 K while its latest quarter income was -84,850 K.
